Neurological Sciences

, Volume 30, Issue 3, pp 251–254 | Cite as

Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report

  • Paola Gaviani
  • A. Silvani
  • E. Corsini
  • A. Erbetta
  • A. Salmaggi
Case Report

Abstract

Neoplastic meningitis from breast cancer often leads to a progressive neurologic deterioration followed by fatal outcome. The therapy is based on the administration of high dose systemic chemotherapy with drugs able to pass through the blood-brain barrier, such as methotrexate (MTX) and cytarabine, cranial or craniospinal irradiation, and intrathecal (IT) administration of MTX and/or cytarabine. However, these approaches only have modest efficacy and are associated with side effects for the patients. A depot formulation of liposomal cytarabine (DepoCyte®) has proven to be useful in clinical trials. We describe the case of a woman with a diagnosis of leptomeningeal carcinomatosis from breast carcinoma who presented cerebrospinal fluid normalization and prolonged complete MRI response to intrathecal chemotherapy with liposomal cytarabine (DepoCyte).

Keywords

Neoplastic meningitis Breast carcinoma Chemotherapy Liposomal cytarabine 

References

  1. 1.
    Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25(2):103–119PubMedCrossRefGoogle Scholar
  2. 2.
    Pentheroudakis G, Pavlidis N (2005) Management of leptomeningeal malignancy. Expert Opin Pharmacother 6(7):1115–1125PubMedCrossRefGoogle Scholar
  3. 3.
    Kim L, Glantz MJ (2001) Neoplastic meningitis. Curr Treat Options Oncol 2(6):517–527PubMedCrossRefGoogle Scholar
  4. 4.
    Chamberlain MC (2006) Neoplastic meningitis. Neurologist 12(4):179–187PubMedCrossRefGoogle Scholar
  5. 5.
    Glantz MJ, Walters BC (1998) Diagnosis and outcome measures in trials for neoplastic meningitis: a review of the literature and clinical experience. Neurosurg Focus 4(6):e4PubMedCrossRefGoogle Scholar
  6. 6.
    Silvani A (2007) Experience with the intrathecal use of liposomal cytarabine at the Besta Institute. Tumori 93(3 Suppl):6–8PubMedGoogle Scholar
  7. 7.
    Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394–3402PubMedGoogle Scholar
  8. 8.
    Rueda Domínguez A, Olmos Hidalgo D, Viciana Garrido R, Torres Sánchez E (2005) Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin Transl Oncol 7(6):232–238PubMedCrossRefGoogle Scholar
  9. 9.
    Esteva FJ, Soh LT, Holmes FA et al (2000) Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 46:382–386PubMedCrossRefGoogle Scholar
  10. 10.
    Jaeckle KA, Batchelor T, O’Day SJ, Phuphanich S, New P, Lesser G et al (2002) An open label trial of sustained-release cytarabine (DepoCyt™) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 7:231–239CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Paola Gaviani
    • 1
  • A. Silvani
    • 1
  • E. Corsini
    • 2
  • A. Erbetta
    • 3
  • A. Salmaggi
    • 1
  1. 1.Neuro Oncology DepartmentFondazione IRCCS Istituto Neurologico Carlo BestaMilanItaly
  2. 2.Laboratory of Clinical AnalysesFondazione IRCCS Istituto Neurologico Carlo BestaMilanItaly
  3. 3.Neuroradiology DepartmentFondazione IRCCS Istituto Neurologico Carlo BestaMilanItaly

Personalised recommendations